Ambry Genetics Announces Launch of their StemArray(TM) Product and Services for High Resolution Characterization of Human Stem Cells
"The StemArray(TM) is the solution for stem cell scientists that are working with Human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells in order to detect genomic abnormalities found in stem cells that would be missed by low resolution karyotyping," said Ardy Arianpour, Ambry's Director of Business Development. "We are offering the StemArray(TM) at a comparable cost to traditional karyotyping and strongly believe that the product and our service will help scientists with new discoveries within this market."
Human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells that are cultured for an extended period of time are susceptible to chromosomal instability, which is a big concern for researchers. Currently, stem cells have been characterized mainly through traditional lowresolution karyotypic analyses, which can only identify large scale aneuploidies over 5 MB in size. The Ambry StemArray(TM) has an average resolution of 43KB throughout the genome and 24KB in RefSeq genes. Resolution is even further enhanced, to the exonic level, in stem cells and cancer related genes.
"As human stem cells begin to make their way into clinical studies, it is essential that the cell lines be thoroughly characterized, added Dr. Aaron Elliott, Ambry's R&D Scientist, Genomics. Using the StemArray(TM) scientists will not only detect the extremely large copy number changes that can be found by karyotype, but also identify very small aberrations that occur during culture that could decrease the reproducibility and reliability of experimental data."
The Ambry StemArray(TM) is ready to be ordered and processed today. For more information on the StemArray(TM) and the full line of Ambry's genomic services, please visit our website at http://www.ambrygen.com
Ambry Genetics is a CAPaccredited, GLPcompliant, CLIAcertified commercial clinical laboratory headquartered in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research. To learn more about testing and services available through Ambry, visit www.ambrygen.com.